Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 5/20 | 0.49 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.49 |
| ▸ | JAK2 | O60674 | 1/20 | 0.48 |
| ▸ | JAK1 | P23458 | 1/20 | 0.48 |
| ▸ | USP30 | Q70CQ3 | 4/20 | 0.46 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.42 |
| ▸ | KLK7 | P49862 | 1/20 | 0.42 |
| ▸ | STS | P08842 | 1/20 | 0.42 |
| ▸ | HTR6 | P50406 | 2/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | HPGDS | O60760 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20515963 | 1.00 | PRMT5 (0.49) | PRMT5WDR77JAK2JAK1USP30 | |
| SCHEMBL18689001 | 0.94 | JAK2 (0.50) | PRMT5WDR77JAK2JAK1USP30 | |
| SCHEMBL20515959 | 0.94 | JAK2 (0.50) | PRMT5WDR77JAK2JAK1USP30 | |
| SCHEMBL18669297 | 0.87 | LMNA (0.39) | BCHE | |
| SCHEMBL18669294 | 0.87 | LMNA (0.39) | BCHE | |
| SCHEMBL12607067 | 0.86 | PRMT5 (0.56) | PRMT5WDR77JAK2JAK1USP30 | |
| SCHEMBL29117319 | 0.86 | PRMT5 (0.56) | PRMT5WDR77JAK2JAK1USP30 | |
| SCHEMBL12607070 | 0.86 | PRMT5 (0.56) | PRMT5WDR77JAK2JAK1USP30 | |
| SCHEMBL18669284 | 0.80 | SMN1; SMN2 (0.41) | BCHE | |
| SCHEMBL18669285 | 0.80 | SMN1; SMN2 (0.41) | BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10370356-B2 | Pyridinone dicarboxamide for use as bromodomain inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2019-08-06 | — | — | US | disclosed |
| US-10370356-B2 | Pyridinone dicarboxamide for use as bromodomain inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2019-08-06 | — | — | US | disclosed |
| US-20180282301-A1 | PYRIDINONE DICARBOXAMIDE FOR USE AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2018-10-04 | — | — | US | disclosed |
| WO-2017050714-A1 | PYRIDINONE DICARBOXAMIDE FOR USE AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10370356-B2 | Pyridinone dicarboxamide for use as bromodomain inhibitors | BRD4, BRD3, BRDT | PRMT5 551/4885WDR77 1141/4885JAK2 788/4885 |
| US-20180282301-A1 | PYRIDINONE DICARBOXAMIDE FOR USE AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRDT | PRMT5 551/4885WDR77 1141/4885JAK2 788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.